| |
Latest 10 SEC filings (by transaction date) for GBIO within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 17/24 | Apr 15/24 | Stanton Matthew | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,674 | |
Apr 17/24 | Apr 15/24 | Stanton Matthew | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -492 | $3.70 |
Apr 17/24 | Apr 15/24 | Stanton Matthew | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,674 | |
Apr 17/24 | Apr 15/24 | Samayoa Phillip | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,147 | |
Apr 17/24 | Apr 15/24 | Samayoa Phillip | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -337 | $3.70 |
Apr 17/24 | Apr 15/24 | Samayoa Phillip | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,147 | |
Apr 17/24 | Apr 15/24 | Paone Antoinette | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,592 | |
Apr 17/24 | Apr 15/24 | Paone Antoinette | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -468 | $3.70 |
Apr 17/24 | Apr 15/24 | Paone Antoinette | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,592 | |
Apr 17/24 | Apr 15/24 | Norkunas Matthew | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,673 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for GBIO within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 17/24 | Apr 15/24 | Stanton Matthew | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,674 | |
Apr 17/24 | Apr 15/24 | Stanton Matthew | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -492 | $3.70 |
Apr 17/24 | Apr 15/24 | Stanton Matthew | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,674 | |
Apr 17/24 | Apr 15/24 | Samayoa Phillip | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,147 | |
Apr 17/24 | Apr 15/24 | Samayoa Phillip | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -337 | $3.70 |
Apr 17/24 | Apr 15/24 | Samayoa Phillip | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,147 | |
Apr 17/24 | Apr 15/24 | Paone Antoinette | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,592 | |
Apr 17/24 | Apr 15/24 | Paone Antoinette | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -468 | $3.70 |
Apr 17/24 | Apr 15/24 | Paone Antoinette | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 1,592 | |
Apr 17/24 | Apr 15/24 | Norkunas Matthew | Direct Ownership | Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -1,673 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |